Physician profile
Jose E Vasquez
NPI 1184667198
$5,935.74
in general payments reported to CMS, 2019-2025
20 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $238 · 2021: $45.01 · 2022: $501 · 2023: $1,066 · 2024: $1,510 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,500 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,499.64 |
| Education | $200.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,201.22 | 2019-2025 | Arikayce, Brinsupri |
| Abbvie INC. | $871.07 | 2022-2025 | Mavyret, Dalvance |
| Viiv Healthcare Company | $815.06 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Melinta Therapeutics, LLC | $774.85 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Merck Sharp & Dohme LLC | $451.75 | 2019-2025 | Zerbaxa, Dificid, Zinplava |
| Gilead Sciences, INC. | $340.84 | 2019-2025 | Biktarvy |
| Astellas Pharma US INC | $254.07 | 2024-2025 | Cresemba |
| Aimmune Therapeutics, INC. | $249.77 | 2024-2025 | Vowst, Zenpep |
| La Jolla Pharmaceutical Company | $212.14 | 2024-2025 | Xerava, Zevtera |
| Ferring Pharmaceuticals INC. | $206.75 | 2023-2025 | Rebyota |
| Paratek Pharmaceuticals, INC. | $177.23 | 2023-2025 | Nuzyra |
| Shionogi INC | $161.60 | 2023-2025 | Fetroja |
| Janssen Biotech, INC. | $71.49 | 2019-2020 | |
| Electromed, INC. | $57.28 | 2025 | Smartvest |
| Tetraphase Pharmaceuticals, INC. | $30.35 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $19.53 | 2025 | Gamunex-C |
| Convatec INC. | $15.34 | 2023 | |
| Shire North American Group INC | $13.70 | 2019 | |
| Theratechnologies INC. | $11.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.